Clinical readout

Novo links Wegovy to liver and weight gains in real-world MASH studies

Two retrospective analyses tied Wegovy use in adults with MASH to larger drops in liver enzymes, weight and HbA1c. In one, patients lost an adjusted 18.9 lb over six months on Wegovy against 5.6 lb on resmetirom, though resmetirom cut LDL more. Neither study was randomized, so the results cannot show cause and effect.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call